UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
Abstract: With the rapid development of Internet of Things (IoT), biometric-based authentication systems have been widely used for access control. The wide application of biometric recognition systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback